statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Tenaya Therapeutics (NASDAQ:TNYA  Free Report) had its price target lowered by Canaccord Genuity Group from $19.00 to $18.00 in a research note issued to investors on Wednesday, Benzinga...

Tenaya Therapeutics (NASDAQ:TNYA) PT Lowered to $18.00 at Canaccord Genuity Group

HC Wainwright reiterated their buy rating on shares of Tenaya Therapeutics (NASDAQ:TNYA  Free Report) in a research report released on Tuesday morning, Benzinga reports. The firm currently...

Tenaya Therapeutics (NASDAQ:TNYA) Earns Buy Rating from HC Wainwright

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Vera Therapeutics (VERA Research Report), Tyra Bioscience (TYRA...

Analysts' Opinions Are Mixed on These Healthcare Stocks: Vera Therapeutics (VERA), Tyra Bioscience (TYRA) and Tenaya Therapeutics (TNYA)

Tenaya Therapeutics (NASDAQ:TNYA  Free Report) had its price target lowered by Canaccord Genuity Group from $19.00 to $18.00 in a research report released on Wednesday morning, Benzinga...

Tenaya Therapeutics (NASDAQ:TNYA) Given New $18.00 Price Target at Canaccord Genuity Group

Biotech Firm Prepares for Clinical Trials with Extended Cash RunwayRelated Stocks: TNYA...

Tenaya Therapeutics Inc Reports Full Year and Q4 2023 Financial Results

Theres a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Inventiva (IVA Research Report) and Tenaya Therapeutics...

Analysts' Top Healthcare Picks: Inventiva (IVA), Tenaya Therapeutics (TNYA)

Investors eyeing a purchase of Tenaya Therapeutics Inc (TNYA) stock, but tentative about paying the going market price of 4.53/share, might benefit from considering selling puts among the...

Commit To Buy Tenaya Therapeutics At $2.50, Earn 17.9% Annualized Using Options

Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA  Get Free Report) have earned a consensus rating of Buy from the seven brokerages that are currently covering the company...

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives Average Recommendation of "Buy" from Analysts

TN-401 AAV9-Based Gene Therapy Being Developed to Treat the Underlying Cause of PKP2-associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) PKP2 Gene Replacement Therapy Normalized Heart...

Tenaya Therapeutics Announces Publication of TN-401 Gene Therapy Preclinical Data in Nature Communications Medicine

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Tenaya Therapeutics reports Q4 EPS (40c), consensus (44c)

Tenaya Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapeutics for cardiovascular diseases. It operates through its product platforms: gene therapy, cellular regeneration, and precision medicine. The company was founded by Deepak Srivastava, Benoit G. Bruneau, Bruce R. Conklin, Sheng Ding, Saptarsi Haldar, and Eric Olson in 2016 and is headquartered in South San Francisco, CA.

Volume	46,185.00
52-Wk High	$8.09
52-Wk Low	$1.66

TNYA Tenaya Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals